Apyx Medical Reports Q3 Earnings Beat and Reaffirms FY26 Outlook
Apyx Medical (APYX) reported third-quarter financial results that exceeded both top-line and bottom-line analyst expectations. The company achieved a GAAP EPS of -$0.04, outperforming estimates by $0.05, while revenue grew 8.5% year-over-year to reach $14 million, surpassing projections by $0.71 million. Notably, the company transitioned to a positive Adjusted EBITDA of $0.4 million for the quarter ending September 30, 2026, compared to an Adjusted EBITDA loss of $0.1 million in the prior year period. Following these results, Apyx Medical has reaffirmed its financial outlook for fiscal year 2026.
Tickers: $APYX
Topics: earnings beat EBITDA improvement revenue growth
Read the full article at Seeking Alpha
Part of the story CSW Industrials Reports Q2 2027 Earnings Beat with Record Adjusted EBITDA (25 articles)